News

CADTH is pleased to announce the election of 3 new members to the CADTH Board of Directors. “On behalf of the Board, I am pleased to welcome Louise Taylor Green, Dr. Jeffrey Tyberg, and Robert Shaffer as directors," said David Agnew, Board Chair. "Each of these remarkable individuals brings unique…
The international collaboration between 6 health technology assessment (HTA) bodies from across the UK, Australia, and Canada welcomes 2 further HTA bodies. The addition of the Institut national d’excellence en santé et en services sociaux (INESSS) (Quebec) and Pharmac (New Zealand) to the…
CADTH is establishing an industry task force that will build upon the recently released Guidance for Reporting Real-World Evidence to provide advice on the use of industry-generated real-world data (RWD) in its Post-Market Drug Evaluation (PMDE) Program. We are inviting industry representatives to…
A message from Suzanne McGurn, President and CEO, CADTH On behalf of CADTH and our Board of Directors, I’m pleased to share the CADTH Annual Report for 2022–2023. The theme of this year’s report, Ahead of the Curve, aligns with our strategic plan and our efforts to shape a future-ready health…
As CADTH continues along the path of strategic transformation, we’re working hard to align the evidence products we deliver with the priority needs of decision-makers in Canada. As part of this work, CADTH has made the decision to retire Reference Lists as a standard offering in our evidence…
The CADTH Weekly Summary is an email newsletter sent every Thursday to bring subscribers important notifications about CADTH drug reimbursement reviews, including input and feedback opportunities, the publication of draft and final drug reimbursement recommendations, and procedural updates. CADTH…
New committee will trial novel  approaches to drug reviews and expand support for decision-makers to unleash the value of drugs across their lifespan. CADTH, Canada’s drug and health technology agency, announces the creation and inaugural membership of a new Formulary Management Expert Committee as…
Today, CADTH is communicating a series of improvements that will further our ambition to innovate in the field of health technology assessment (HTA), adapt to changing regulatory and reimbursement environments, and improve the pathway that brings effective drugs to patients across Canada. During…
CADTH, Health Canada, and the Institut national d’excellence en santé et en services sociaux (INESSS) are seeking to advance the use of real-world evidence in regulatory and health technology assessment decision-making A final guidance document published today provides important direction on…
CADTH presents its top awards for career achievement to Dr. Brian O’Rourke and Dr. Kednapa Thavorn during the 2023 CADTH Symposium. Ottawa, May 16, 2023 — Today, CADTH, Canada’s drug and health technology agency, announced the recipients of its 2023 Recognition Awards. These prizes honour…
During a 1-year learning period, CADTH expanded its Scientific Advice program to include advice on real-world evidence (RWE), allowing applications after lockdown of protocols for pivotal trials. Based on the positive experience and considerable interest from industry, CADTH is formalizing this…
The position statement is a step toward greater transparency of unpublished data and a tangible outcome resulting from cooperation among global health technology assessment bodies CADTH, Canada’s drug and health technology agency, in collaboration with the Institute for Clinical and Economic Review…